Kalinsky K, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Farley CR, Bassett RL, Meric-Bernstam F, et al. To dissect or not to dissect: Can we predict the presence of four or more axillary lymph node metastases in postmenopausal women with clinically node negative breast cancer? Ann of Surg Oncol. 2023. https://doi.org/10.1245/s10434-023-14245-1.

Article  Google Scholar 

Johnston SRD, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987–98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Slamon DJ, et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: Primary results from the phase III NATALEE trial. J Clin Oncol. 2023;41(17_suppl):LBA500.

Article  Google Scholar 

Addanki S, et al. Applications of circulating tumor cells and circulating tumor DNA in precision oncology for breast cancers. Int J Mol Sci. 2022;23(14):7843.

Article  CAS  PubMed  PubMed Central  Google Scholar